Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.91 USD
-0.07 (-6.68%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $0.92 +0.01 (1.10%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Brokerage Reports
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 81 - 100 ( 323 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Pipeline Taking Shape; HemA at ASH; Initial Fabry Data by YE:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hem A on the Clock; Phase 3 Underway Triggering $30M Milestone Payment
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
NVS Deal Offers Look Into R-D Royalty Aggregator Model; HemA GeneTx, Q2 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Does the Buck Stop at the Two Year Annualized Bleeding Rate
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Update; the Hum You Hear is the BD Team in Action
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Full Measure to Address Host Rejection
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
How Far We''ve Come, How Little We Know
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SB-525 Early Promise Regresses to the Mean; Target Lowered to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SB-525/Hemophilia A: New Long-Term Follow-up Phase 1/2 Data at WFH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1; Long-Term SB-525/Hemophilia A Phase 1/2 Data at WFH on June 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SB-525 Marches on; But the Pandemic Forces Pipeline Delays
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts Post-LSD KOL Dinner; Bottom line - It?s AAV?s Over Lenti?s
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY19 Financials, Partnership - Pipeline Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
From TINA to Cash Is King and Other Musings
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY19 Corporate Update in the Backdrop of Another Big Preclinical Transaction
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Runners up Is the New Killing It, and Other Tidbits
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Let?s Caucus, or Never Again; In an Otherwise Ho-Hum Earnings Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D